La lezione del Coronavirus

Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 by Age Group in Italy

Luigi Palmieri, PhD, Nicola Vanacore, MD, Graziano Onder, MD, PhD and the Italian National Institute of Health COVID-19 mortality group,
The Journals of Gerontology, June 2020

Comorbidities, symptoms, complications, and treatments in COVID-19 patients who die, according to age group – 1.

|	All (n = 3,032)	Younger Adults <65 y (n = 368)	Older Adults ≥ 65 y (n = 2,664)	p-Value[a]
	n (%)	n (%)	n (%)	
Comorbidities				
Ischemic heart disease	856 (28.2)	42 (11.4)	814 (30.6)	<.001
Atrial fibrillation	681 (22.5)	18 (4.9)	663 (24.9)	<.001
Heart failure	490 (16.2)	31 (8.1)	459 (16.9)	<.001
Stroke	310 (10.2)	16 (4.3)	294 (11.0)	<.001
Hypertension	2,071 (68.3)	188 (51.1)	1,883 (70.7)	<.001
Type 2 diabetes	914 (30.1)	106 (28.8)	808 (30.3)	.586
Dementia	480 (15.8)	12 (3.3)	468 (17.6)	<.001

Comorbidities, symptoms, complications, and treatments in COVID-19 patients who die, according to age group – 2.

	All (n = 3,032)	Younger Adults <65 y (n = 368)	Older Adults ≥ 65 y (n = 2,664)	p-Value[a]
	n (%)	n (%)	n (%)	
COPD	498 (16.4)	41 (11.1)	457 (17.2)	.003
Active cancer	480 (15.8)	56 (15.2)	424 (15.9)	.761
Chronic liver disease	120 (4.0)	24 (6.5)	96 (3.6)	.010
Chronic renal failure	618 (20.4)	42 (11.4)	576 (21.6)	<.001
Dialysis	55 (1.8)	9 (2.4)	46 (1.7)	.301
HIV	6 (0.2)	4 (1.1)	2 (0.1)	.003
Autoimmune diseases	115 (3.8)	15 (4.1)	100 (3.8)	.770
Obesity	335 (11.0)	108 (29.3)	227 (8.5)	<.001

Comorbidities, symptoms, complications, and treatments in COVID-19 patients who die, according to age group – 3.

	All (n = 3,032)	Younger Adults <65 y (n = 368)	Older Adults ≥ 65 y (n = 2,664)	p-Value[a]
	n (%)	n (%)	n (%)	
No. of comorbidities				
0	124 (4.1)	40 (10.9)	84 (3.2)	<.001
1	454 (15.0)	85 (23.1)	369 (13.9)	
2	648 (21.4)	82 (22.3)	566 (21.2)	
3 or more	1,806 (59.6)	161 (43.8)	1,645 (61.7)	

Età media per data di decesso

Weekly deaths mean age (all weeks)

Decessi per COVID

Periodo	Età Media	Almeno 3 comorbidità
Marzo-Maggio	80.1 anni	62.7%
Giugno-Agosto	82.7 anni	81.0%

Persistent Symptoms in Patients After Acute COVID-19

Angelo Carfì, MD[1]; Roberto Bernabei, MD[1]; Francesco Landi, MD, PhD[1]; et al

» Author Affiliations | Article Information

on behalf of the Gemelli Against COVID-19 Post-Acute Care Study Group

Department of Geriatrics

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, IT

ITALIA LONGEVA
PER L'INVECCHIAMENTO E LA LONGEVITÀ ATTIVA

Results

Figure. COVID-19–Related Symptoms

The figure shows percentages of patients presenting with specific coronavirus disease 2019 (COVID-19)–related symptoms during the acute phase of the disease (left) and at the time of the follow-up visit (right).

Table. Demographic and Clinical Characteristics of the Study Sample (N = 143)

Characteristics	Value
Age, mean (SD), y	56.5 (14.6)
Female sex, No. (%)	53 (37.1)
Post-acute COVID-19 follow-up characteristics	
Days since symptoms onset, mean (SD)	60.3 (13.6)
Days since discharge, mean (SD)	36.1 (12.9)
Persistent symptoms, No. (%)	
None	18 (12.6)
1 or 2	46 (32.2)
≥3	79 (55.2)